Companies:64525
FatCapitalist:Apple Inc. [AAPL]United States

Neuren Pharmaceuticals Limited [NURPFAustralia

Other OTC exchange. Sector: Healthcare. Industry: Biotechnology. Location Australia, Camberwell.
At close Wed Sep 28 2022
4.28 USD 👎0.28 (-6.54%)

At close Wed Sep 28 2022

Marketcap
555,073,216 USD

Marketcap

PE:.
BETA (5y):1.772
EPS:-0.066
Profits

for 5 years

286%

for 3 years

380%

for 2 years

139%

for 1 year

338%

for this year

112%
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.

Neuren Pharmaceuticals Limited
© 2022 avazzy.com. All rights reserved
Make with 🤎 and ☕ for you!

Investing involves risk, including possible loss of principal.

The strategies discussed are strictly for illustrative and educational purposes and are not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. There is no guarantee that any strategies discussed will be effective.

International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation and the possibility of substantial volatility due to adverse political, economic or other developments. These risks often are heightened for investments in emerging/ developing markets or in concentrations of single countries.